Trastuzumab, a recombinant mAb binding to the extracellular domain of HER2, is the first-line recommended drug for HER2+ BC patients and has been proved to prolong survival of HER2+ BC patients [3]. The gene discussed is ERBB2; the disease is breast cancer.